AstraZeneca PLC’s Imfinzi extended the lives of patients with bladder cancer, potentially opening up a new market for the blockbuster medicine.
In patients with muscle-invasive bladder cancer, Imfinzi reduced the risk of disease recurring by 32% when given alongside the current standard of care, interim analysis of a late-stage trial found.
The medicine also reduced the risk of death by a quarter when added to current treatments such as chemotherapy and surgery, according to the study involving 1,063 patients.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.